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Abstract: Rosmarinic acid (RA) possesses several protective bioactivities that have attracted 
increasing interest by nutraceutical/pharmaceutical industries. Considering the reduced 
bioavailability after oral use, effective (and safe) delivery systems are crucial to protect RA 
from gastrointestinal degradation. This study aims to characterize the safety profile of solid lipid 
nanoparticles produced with Witepsol and Carnauba waxes and loaded with RA, using in vitro 
and in vivo approaches, focused on genotoxicity and cytotoxicity assays, redox status markers, 
hematological and biochemical profile, liver and kidney function, gut bacterial microbiota, and 
fecal fatty acids composition. Free RA and sage extract, empty nanoparticles, or nanoparticles 
loaded with RA or sage extract (0.15 and 1.5 mg/mL) were evaluated for cell (lymphocytes) 
viability, necrosis and apoptosis, and antioxidant/prooxidant effects upon DNA. Wistar rats were 
orally treated for 14 days with vehicle (control) and with Witepsol or Carnauba nanoparticles 
loaded with RA at 1 and 10 mg/kg body weight/d. Blood, urine, feces, and several tissues were 
collected for analysis. Free and loaded RA, at 0.15 mg/mL, presented a safe profile, while 
genotoxic potential was found for the higher dose (1.5 mg/mL), mainly by necrosis. Our data 
suggest that both types of nanoparticles are safe when loaded with moderate concentrations 
of RA, without in vitro genotoxicity and cytotoxicity and with an in vivo safety profile in rats 
orally treated, thus opening new avenues for use in nutraceutical applications.
Keywords: solid lipid nanoparticles, rosmarinic acid, Witepsol and Carnauba waxes, safety 
profile, in vitro and animal toxicity
Introduction
Rosmarinic acid (RA) is a natural polyphenol carboxylic acid, an ester of caffeic acid 
with 3,4-dihydroxyphenyllactic acid,1 found in many species, used as culinary herbs 
(including Salvia officinalis – sage), and possessing several biological activities related 
to health promotion, including antioxidant, anti-inflammatory, and anticarcinogenic 
properties.2 There is a growing interest on the possibility of polyphenols application 
(including RA) in functional foods, nutraceutical, and pharmaceutical industries.2–5 
However, the effectiveness of polyphenols depends on preserving the stability and 
bioavailability of the active ingredients.
In this regard, strategies to improve oral bioavailability are crucial for the develop-
ment of more effective therapies. A major example is the incorporation of polyphenols 
in dairy matrices, which is not feasible because of their interaction with matrix com-
ponents (eg, protein).2 These interactions destabilize these compounds and decrease 
their bioavailability after being ingested; furthermore, conformational changes in their 
structure can occur during exposure to gastric and intestinal juices, and especially to 
correspondence: Flávio reis
laboratory of Pharmacology and 
experimental Therapeutics, Institute for 
Biomedical Imaging and life sciences (IBIlI), 
Faculty of Medicine, sub-Unit 1 (Pólo III), 
University of coimbra, 3000-548 coimbra, 
Portugal
Tel +351 23948 0053
Fax +351 23948 0065
email freis@fmed.uc.pt 
Journal name: International Journal of Nanomedicine
Article Designation: Original Research
Year: 2016
Volume: 11
Running head verso: Madureira et al
Running head recto: Safety profile of solid lipid nanoparticles loaded with rosmarinic acid
DOI: http://dx.doi.org/10.2147/IJN.S104623
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3622
Madureira et al
the intestinal microflora.2 Hence, a delivery system, such 
as a formulation of solid lipid nanoparticles (SLN), could 
be essential to protect the polyphenols from these events, 
thus improving bioavailability and retaining their beneficial 
biological properties.
Recently, our group developed SLN for oral delivery 
of RA or enriched herbal extracts, such as sage and savory; 
the resulting SLN had mean diameters between 270 and 
1,000 nm and ~99% of association efficiencies and were 
highly stable.6–8 Witepsol and Carnauba waxes were used to 
produce these systems. Witepsol is a synthetic wax usually 
not only used in the pharmaceutical industry as excipient but 
also approved for human consumption; Carnauba wax (also 
named Brazilian wax) is naturally extracted from the leaves 
of a particular palm tree known as Copernicia cerifera, a 
plant native to the northeast of Brazil.9–12 The encapsulation of 
such polyphenols has afforded, in vitro, protection against the 
digestive harsh conditions and has improved bioavailability.8 
Oral administration of SLN is the most attractive route due 
to its unquestionable commercial potential, but it continues 
to be a major challenge.13 The advantages associated are 
the possibility of drug protection from hydrolysis and the 
increased bioavailability, thus improving the therapeutic 
performance. Prolonged plasma levels have also been pos-
tulated due to a controlled and optimized release in combi-
nation with general adhesive properties of small particles.14 
In addition, oral administration is the most practical and the 
best accepted route by consumers/patients for long-term 
administration of phytochemicals and dietary supplements.
New nutraceutical or therapeutic strategies need to 
not only prove improved efficacy when compared to the 
preexisting options but also, and particularly, must show a 
safe profile. The potential adverse effects of new engineered 
nanoparticles have been extensively investigated in vivo and 
in vitro.15–19 Animal studies are indeed good tools to study 
potential effects of oral administration of drugs or bioactive 
compounds, as well as to evaluate the body distribution of 
these compounds when transported via nanoparticles.14 With 
regard to nanoformulations that are to transport polyphenols 
incorporated in dairy matrices, animal models are essential 
to evaluate the presence and concentration of phenolic com-
pounds in the gastrointestinal tissues and body fluids (such 
as blood, urine, and feces), as well as to access the putative 
impact on gut microbiota and on feces composition on fatty 
acids, which are pivotal to this type of formulations. Thus, 
it is established that in vivo studies in animal models are 
very important to elucidate the toxicity of nanomaterials but 
should be preceded by in vitro assays.20,21
For this purpose, in vitro tests are available for testing the 
genotoxicity of compounds in cells. The cytokinesis-block 
micronucleus cytome (CBMN cyt) assay is a reliable stan-
dard and reproducible assay for testing genotoxicity in both 
human and other mammalian cells, including lymphocytes.22 
In particular, this refined protocol focuses on the different 
types of DNA damage that can be detected, such as DNA 
misrepair, chromosome breakage or loss, nondisjunction, 
cytostasis, cytotoxicity, as well as necrosis and apoptosis. The 
CBMN assay has been demonstrating positive outcomes for a 
wide range of nanomaterials, such as Co NPs (100–500 nm), 
Co–Cr alloy NPs (30 nm), TiO
2
 NPs (25; 10–20; #20 nm), 
SiO
2
 NPs (6.6, 8.2, 196 nm), polyaspartic acid-coated magne-
tite NPs (8.5 nm), water-soluble C60 (7.1 nm), and mwCNTs 
(11.3 nm diameter, 700 nm length), using different cell 
types.22 On the other hand, nanoparticles can be evaluated for 
their ability to act, under specific conditions, as prooxidant-
free radicals, thus leading to DNA oxidation, which is often 
a concentration dependent effect.23 For such purpose, in vitro 
tests using DNA agarose gel can be done to obtain DNA 
strands in intact or fragmented (oxidized) state. In this regard, 
although most of the nanoparticles toxicity tests are done in 
red blood cells (RBCs) and macrophages, lymphocytes are 
a feasible good alternative.22
In this study, a thorough evaluation of putative toxico-
logical properties of SLN loaded with RA was made, using 
in vitro and in vivo (rat) approaches, focused on genotoxicity 
and cytotoxicity assays, redox status markers, hematologi-
cal and biochemical profile, liver and kidney function, gut 
bacterial microbiota, and fecal fatty acids composition.
Materials and methods
herbs extracts preparation
Leaves of sage (S. officinalis) and savory (Satureja montana) 
herbs were milled to a powder form and 1 g was added to 
110 mL of boiling deionized water, which was left to cool 
by mixing for 5 minutes. The solution was filtered through 
number 1 filter paper (V Reis, Lisboa, Portugal), frozen, and 
then freeze-dried (Model FT33, Armefield, Hampshire, UK) 
under a vacuum pressure (100 mTorr), with temperatures 
of -46°C in freezing chamber and 15°C in sample cham-
ber. Dried extracts were characterized in terms of phenolic 
compounds by high-performance liquid chromatography 
(HPLC) assays.
slN production method
SLN were produced according to the method previously 
described.6,7 The waxes used were Witepsol H15 (Sasol, 
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Hamburg, Germany) and Carnauba wax yellow number 1 
(Sigma-Aldrich, St Louis, MO, USA). Surfactant polysorbate 
(Tween 80) and RA were purchased from Sigma-Aldrich. 
Briefly, SLN were prepared by hot-melt ultrasonication, 
loading the RA and herbal aqueous extracts at the final 
concentration of 0.15 mg RA/mL. The lipid at 0.5% (w/v) 
was warmed to a temperature of 5°C above the melting 
point (36°C for Witepsol and 86°C for Carnauba), then the 
melted matrix was added with RA or herbal extracts and 
subjected to ultrasonication (VCX 130, Sonics & Materials, 
Newtown, CT, USA) for 1 minute at 70% of intensity. 
Finally, the aqueous surfactant solution of polysorbate 80 
was added to obtain a final concentration of 2% (v/v) and 
mixed for a few seconds, for completely homogenization of 
the O/W emulsion. The resulting fluid solutions were left to 
cool at room temperature (20°C). The SLN emulsions were 
stored at 5°C for 28 days until further use. When dried SLN 
were used, the emulsions were freeze-dried upon production 
using a vacuum freeze drier (Model FT33), under a vacuum 
pressure of 100 mTorr; the temperature in the freezing 
chamber was -46°C, and the temperature in the sample 
chamber was 15°C.
slN characterization techniques
Physical properties
Particle size, polydispersity index, and zeta potential were 
measured using dynamic light scattering (DLS) ZetaSizer 
NanoZSP (Malvern Instruments, Malvern, UK). Zeta poten-
tial was measured using laser Doppler anemometry. All 
analyses were carried out at an angle of 90°C at 25°C.
Association efficiency
Centrifugation at 4,200× g (20 minutes at 4°C) using cen-
trifugal filter units with a cutoff of 10 K (Amicon® Ultra-4, 
Millipore, MA, USA) was performed to separate nonen-
trapped compounds from SLN aqueous solution. The RA 
concentration was quantified in the resulting supernatant by 
HPLC analysis as previously described.6 The association 
efficiencies of RA and extracts (AE%) were calculated 
according to the following formula:
  
AE%
Totalamount of PC Amount of PCinsupernatant
Totalamount of PC
=
−
×100,
 (1)
where AE% is the association efficiency percentage and PC 
is phenolic compound (RA in the case of SLN-RA).
evaluation of genotoxicity by cytokinesis-
blocked micronucleus cytome assay
Fresh peripheral blood samples were collected from each 
individual into heparinized vacutainers. Whole blood samples 
were then suspended in Roswell Park Memorial Institute 
(RPMI) 1640 culture medium, supplemented with 10% 
(w/v) fetal bovine serum (FBS), l-glutamine, penicillin, 
and phytohemagglutinin (at 1% [w/v] – used as mitogen to 
stimulate lymphocyte mitosis). In all sets of experiments 
(n=3), a negative control (whole blood in phosphate-buffered 
saline, PBS) was used, as well as a positive control (using 
the mutagenic agent cyclophosphamide, at 5 µg/mL). Dried 
SLN (empty and loaded) and free compounds were used in 
order to obtain the final concentrations of 1.5 and 0.15 mg/mL 
of RA and sage extracts. Duplicate cultures were set up for 
each experimental point, within 60 minutes after venipunc-
ture. Cytochalasin B – an inhibitor of mitotic spindle that 
prevents cytokinesis – was added at 5 µg/mL for 44 hours 
and incubated at 37°C and was then discontinued 72 hours 
after experiment initiation.
The lymphocytes were isolated from other blood cells 
by density gradient separation (Histopaque 1077 and 1119, 
Sigma-Aldrich). After lymphocyte purification, the cells were 
fixed in 3:1 methanol/glacial acetic acid mixture, dropped 
onto clean microscopic slides, air-dried, and stained with 
Wright stain. For each sample, 1,000 binucleated cells were 
blindly scored using a Leica light optical microscope (Leica 
Microsystems, Wetzlar, Germany), following the scoring 
criteria outlined elsewhere;24 the number of micronuclei, 
nucleoplasmic bridges, and nuclear buds per 1,000 binucle-
ated cells were recorded. The nucleus division index (NDI), a 
measure of the cell division kinetics, was scored in the same 
slides for micronuclei, according to the method of Eastmond 
and Tucker;25 500 viable cells were accordingly counted to 
determine the frequency of cells with 1–4 nuclei, and the NDI 
calculated using the formula:
 NDI = (M1+2M2+3M3+4M4)/N (2)
where M1–M4 represent the number of cells with 1–4 nuclei, 
respectively, and N is the total number of viable cells scored 
(excluding necrotic and apoptotic cells).
Evaluation of cytotoxicity by flow 
cytometry
Fresh peripheral blood samples were collected and treated 
as described earlier for cytokinesis-blocked micronucleus 
assay. Cell viability assessment of the pure lymphocytes was 
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performed by trypan blue exclusion test, using a Neubauer 
counting chamber. Lymphocytes were then resuspended, 
at a concentration of 1×106 viable cells/mL, in RPMI 
1640, supplemented with 10% (w/v) FBS, l-glutamine, 
and penicillin. In all sets of experiments (n=3), a negative 
control (PBS) was used, as well as a positive control with 
staurosporine at 4 µM – a strong cytotoxic alkaloid – added 
8 hours before the end of incubation. Amounts of dried 
SLN were used to obtain the final concentrations of 1.5 
and 0.15 mg/mL of RA and sage extracts, respectively, and 
incubated for 24 hours at 37°C. After incubation, the cells 
were stained according to the general Annexin V staining 
procedure (Annexin V-PE apoptosis detection kit I, BD 
Biosciences, San Jose, CA, USA). Cells were analyzed by 
flow cytometry within a 1-hour period.26,27
DNa assay by agarose gel 
electrophoresis
SLN and free compounds were tested at a concentration 
of 0.15 mg/mL. DNA interaction assay was performed 
according to the protocol previously described.23 A 400 µL 
aliquot of sample was initially prepared and processed 
(as will be detailed), as well as 100 mM standard solu-
tion of ascorbic acid. This method includes assays of both 
controls and samples and evaluates both anti- and prooxidant 
properties. Different conditions were considered toward 
this purpose: 1) positive control, using 800 µL of 100 mM 
sodium phosphate buffer (pH 7.4) and 200 µL of 0.25 mg/mL 
DNA; 2) negative control, using 690 µL of 100 mM sodium 
phosphate buffer (pH 7.4), 200 µL of 0.25 mg/mL DNA, 
100 µL of 100 mM ascorbic acid, and 10 µL of 10 mM Cu2+; 
3) antioxidant effect of samples, using 290 µL of 100 mM 
sodium phosphate buffer (pH 7.4), 200 µL of 0.25 mg/mL 
DNA, 400 µL of sample, 100 µL of 1 mM ascorbic acid, 
and 10 µL of 100 mM Cu2+; and 4) prooxidant effect of 
samples, using 400 µL of 100 mM sodium phosphate buf-
fer (pH 7.4), 200 µL of 0.25 mg/mL DNA, and 400 µL of 
sample. Following incubation for 1 hour at 37°C, 50 µL 
aliquots were mixed with 10 µL of loading buffer (to 20 mL 
glycerol were added 10 mL of 2.5 g/L of bromophenol blue 
in TE 1× solution) and 10 µL was loaded on 1% agarose gel. 
Electrophoresis was carried out for 30 minutes at 150 V in 
tris–acetate–ethylenediaminetetraacetic acid (EDTA) buffer. 
DNA bands were finally digitalized using Gel Doc (Bio-Rad 
Laboratories Inc., Hercules, CA, USA).
animals and treatments
Male Wistar rats, weighing 290–310 g (Charles River Labora-
tories, Barcelona, Spain), were housed in racks of individual 
ventilated cages, subjected to 12 hours dark/light cycles 
and given standard laboratory rat chow (IPM-R20, Letica, 
Spain) and free access to tap water. Animal experiments were 
conducted according to the European Council Directives on 
Animal Care and to the National Authorities, and approved 
by the local ethics committee (Orgão Responsável pelo Bem 
Estar animal [ORBEA]). Animals were acclimatized to labo-
ratory conditions 1 week before initiation of treatments. The 
rats were randomly divided into five groups, receiving the fol-
lowing oral (gavage) treatments for 14 days: control group – 
vehicle (saline); Witepsol groups – received Witepsol-based 
solid lipid nanoparticles (WSLN) loaded with RA at the 
final dose of 1 mg/kg (WSLN-RA1) and 10 mg/kg (WSLN-
RA10); and Carnauba groups – received Carnauba wax-based 
solid lipid nanoparticles (CSLN) loaded with RA at doses of 
1 and 10 mg/kg (CSLN-RA1 and CSLN-RA10), respectively. 
The body weight (BW) of each animal was recorded weekly 
during the experimental period.
collection of biological samples
Blood and tissue collection
After 14 days, rats were anesthetized intraperitoneally with 
2.0 mg/kg BW of a 2:1 (v:v) 50 mg/mL Ketamine (Ketalar®, 
Parke-Davis, Portugal) solution in 2.5% chlorpromazine 
(Largatil®, Rhône-Poulenc Rorer, Amadora, Portugal). Blood 
samples were collected by venipuncture from the jugular vein 
into vacutainer tubes without and with (EDTA) anticoagu-
lant, in order to obtain whole blood, plasma, and serum. The 
rats were sacrificed by cervical dislocation and the follow-
ing tissues collected: heart, liver, kidney, stomach, spleen, 
epididymal white adipose tissue (EWAT), small intestine, 
and cecum. Tissues were weighed and stored in appropri-
ate conditions to perform the assays further described. The 
relative tissue weight was calculated as the ratio of absolute 
tissue weight (g) to BW (kg).
collection of urine and feces
At the final time, 24-hour urine and feces samples were 
collected using metabolic cages. During this period, rats 
had free access to water and food. Feces were weighed, the 
volume of the urine was recorded, and samples were stored 
(-20°C) until later analysis.
hematological and biochemical analyses
The following hematological parameters were determined in 
EDTA whole blood by using an automatic blood cell counter 
(Sysmex K1000, Germany): RBC, white blood cells (WBC), 
and platelet and reticulocyte count, hematocrit (HCT) and 
hemoglobin (HGB) concentration, and hematimetric indices 
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(mean cell volume [MCV], mean cell hemoglobin [MCH], 
and mean cell hemoglobin concentration [MCHC]). The 
following biochemical parameters were assessed in serum by 
using automatic validated methods and equipments (Hitachi 
717 analyzer, Roche Diagnostics Inc., MA, USA): glucose, 
urea, creatinine, uric acid, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), triglycerides (TGs), and 
total cholesterol (Total-Chol).
evaluation of redox status
The thiobarbituric acid reactive-species assay was used to 
assess serum, kidney, and liver products of lipid peroxidation, 
via malondialdehyde (MDA), as previously described.28 
Samples were analyzed spectrophotometrically at 532 nm 
using 1,1,3,3-tetramethoxypropane as the external standard. 
The concentration of lipid peroxides (in MDA) was 
expressed as µmol/L in serum and as µmol/g of tissue in 
the liver and kidney samples. Ferric reducing antioxidant 
potential assay was used to estimate serum total antioxidant 
status (TAS).29
Tissues analysis by transmission electron 
microscopy (TeM)
Tissue samples (heart, liver, kidney, stomach, spleen, EWAT, 
small intestine and cecum) were immediately sectioned in 
small fragments of ~1 mm3 and fixed in 2.5% glutaraldehyde 
solution in 0.1 M phosphate buffer (pH=7.2) for 2 hours. 
Sequential postfixation was performed in 1% osmium 
tetroxide, for 1.5 hours, and 1% aqueous uranyl acetate, for 
1 hour in the dark. After rinsing in distilled water, samples 
were dehydrated in a graded acetone series (30%–100%), 
and embedded using an Epoxy embedding kit (Fluka 
Analytical, Sigma-Aldrich, Germany). Ultrathin sections 
were obtained on a Leica EM UC6 (Leica Co, Austria) 
ultramicrotome and mounted on copper grids and stained 
with lead citrate 0.2% for 10 minutes. Observations were 
carried out on a TEM Tecnai G2 Spirit Bio Twin at 100 kV 
(FEI, Hillsboro, OR, USA), and images were processed 
using AnalySIS 3.2.
Extraction and quantification of 
polyphenols
extraction procedure
Approximately 200 mg of feces and urine (taken 24 hours 
after last feeding), blood serum (taken 12 hours after last 
feeding), and tissues (eg, small intestine and liver) were 
homogenized with 3 mL of PBS solution (0.1 M, pH 7) 
using an Ultra-Turrax homogenizer (IKA digital T18, 
Germany) for 1 minute at 18,000 rpm. To the resulting 
solution, three volumes of methanol were added, mixed, and 
subjected to ultrasonication (VCX130 Ultrasonic processor, 
Sonics, NW, USA) for 15 minutes and then centrifuged at 
11,760× g (10 minutes at 5°C). The pellet was discharged, 
and the supernatant was submitted to filtration with a reverse 
phase column syringe C18 (Waters, MA, USA) to separate 
the phenolic compounds. This procedure was repeated two 
times. The supernatant was filtered through the column, 
retaining the phenolic compounds on the filter. The filter 
was cleaned with 1 mL of an acidified acetonitrile solution 
(C
2
H
3
N:H
2
O:CH
2
O
2
; 50:49:1), and the resulting cleaning 
solution was collected at the end. All solutions were concen-
trated in a speed vacuum and evaporated under acetonitrile. 
The final solutions were evaluated by HPLC method. The 
extraction was made in three samples from each group, and 
the resulting samples were analyzed in triplicate.
Quantification of phenolic compounds by HPLC
Feces were homogenized and centrifuged at 11,760× g for 
15 minutes. The supernatants were filtered with 0.22 µm 
filters (Millipore, Darmstadt, Germany) before analysis. 
The chromatographic assay was performed using a Waters 
e2695 separations module system interfaced with a pho-
todiode array UV/Vis detector and wavelength in the 
range of 190–600 nm. Separation was done in a reverse-
phase column coupled with a guard column containing 
the same stationary phase (Cosmosil 5C18-AR-II packed 
column - 4.6 mm ID ×250 mm, Dartford, Kent, UK). 
Chromatographic separation of phenolic compounds was 
carried out with mobile phase A – water, methanol, and 
formic acid (92.5:5:2.5) – and mobile phase B – methanol, 
water, and formic acid (92.5:5:2.5) – under the following 
conditions: gradient elution starts at 100% mobile phase A 
and ends at 15% after 90 minutes at a continuous flow of 
0.75 mL/minute; between 90 and 100 minutes the mobile 
phase A returns to 100% and remains at this percentage 
for 5 minutes (until 105 minutes). Data acquisition and 
analysis were accomplished using Empower 3 Software 
(Waters, Hertfordshire, UK). Detection was performed at 
wavelengths ranging from 250 to 320 nm. The peaks were 
obtained at 250 nm (rutin) and 260 and 320 nm (RA and 
ferulic acid) and were analyzed by comparison of reten-
tion time and spectra with pure compounds. All phenolic 
compounds were obtained from Sigma-Aldrich Chemistry 
and were of pure (~98%) HPLC-grade standard. Quanti-
fication was performed using calibration curve of each 
compound. Three independent analyses were performed 
for each experiment.
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Extraction and quantification of gut 
bacterial microbiota in feces
DNa extraction from stool
Genomic DNA was extracted and purified from fecal 
samples using NZY Tissue gDNA Isolation Kit (Nzytech, 
Lisboa, Portugal) with some modifications. Briefly, the feces 
(170–200 mg) were homogenized in TE buffer (10 mM Tris/
HCl; 1 mM EDTA, pH 8.0) and centrifuged at 4,000× g for 
15 minutes. The supernatant was discarded and the pellet 
was resuspended in 350 µL of buffer NT1. After an incuba-
tion step at 95°C for 10 minutes, samples were centrifuged 
at 11,000× g for 1 minute. Then, 25 µL of proteinase K was 
added to 200 µL of the supernatant for incubation at 70°C for 
10 minutes. The remaining steps followed the manufacturer’s 
instructions. DNA purity and quantification were assessed 
with a NanoDrop spectrophotometer (Thermo Scientific, 
DE, USA).
Microbial analysis of stool by real-time Pcr
Real-time PCR was performed in sealed 96-well microplates 
using a LightCycler FastStart DNA Master SYBR Green kit 
and a LightCycler instrument (Hoffman-La Roche Ltd). PCR 
reaction mixtures (total of 10 µL) contained 5 µL of 2× Fast-
start SYBR Green, 0.2 µL of each primer (final concentration 
of 0.2 µM), 3.6 µL of water, and 1 µL of DNA (equilibrated 
to 20 ng). Primer sequences (Sigma-Aldrich) used to target 
the 16S rRNA gene of the bacteria and the conditions for 
PCR amplification reactions are listed in Table 1. To verify 
the specificity of the amplicon, a melting curve analysis was 
performed via monitoring SYBR Green fluorescence in the 
temperature ramp from 60°C to 97°C. Data were processed 
and analyzed using the LightCycler software (Hoffman-La 
Roche Ltd). Standard curves were constructed using serial 
tenfold dilutions of bacterial genomic DNA, according to the 
data provided on the following webpage http://cels.uri.edu/
gsc/cndna.html. Bacterial genomic DNA (DSMZ, Germany) 
was used as a standard (Table 1). Genome size and the copy 
number of the 16S rRNA gene for each bacterial strain used 
as a standard were obtained from NCBI Genome database 
(www.ncbi.nlm.nih.gov). Data are presented as the mean 
values of duplicate PCR analysis. The F:B ratio was obtained 
by dividing the number of copies of Firmicutes division by 
the number of copies of Bacteroidetes division.
Extraction and quantification of fatty 
acids in feces
Fatty acids assay
Approximately 500 mg of feces and 10 mg of each 
SLN type (Witepsol and Carnauba) were accurately weighed 
and prepared according to a previously described method.30 
For quantification purposes, samples were added with 50 µL of 
tritridecanoin (1.34 mg/mL in hexane) prior to derivatization, 
and extracts were added with 100 µL of methyl undecanoate 
(1.4 mg/mL in hexane). Esterified fatty acids or fatty acid 
methyl esters (FAMEs) were quantified using a HP 6890A 
gas chromatograph (Hewlett-Packard, PA, USA), equipped 
with a flame-ionization detector (GLC-FID) and a BPX70 
capillary column (50 m ×0.32 mm ×0.25 µm; SGE Europe 
Ltd, France), and analysis conditions were set as previously 
described.31 Supelco 37 FAME mix (Sigma-Aldrich) and 
Table 1 Primer sequences and real-time Pcr conditions used for gut microbiota analysis
Target group Primer sequence (5′–3′) Genomic DNA  
standard
PCR product  
size (bp)
AT (°C)
Universal aaacTcaaaKgaaTTgacgg
cTcacrrcacgagcTgac
Bacteroides vulgatus
aTcc 8482
180 62
Firmicutes aTgTggTTTaaTTcgaagca
agcTgacgacaaccaTgcac
Lactobacillus gasseri
aTcc 33323
126 60
Bacteroidetes caTgTggTTTaaTTcgaTgaT
agcTgacgacaaccaTgcag
Bacteroides vulgatus
aTcc 8482
126 60
Lactobacillus spp. gaggcagcagTagggaaTcTTc
ggccagTTacTaccTcTaTccTTcTTc
Lactobacillus gasseri
aTcc 33323
126 60
Roseburia spp. TacTgcaTTggaaacTgTcg
cggcaccgaagagcaaT
Roseburia hominis
a2-183
230 60
Bacteroides spp. aTagccTTTcgaaagraagaT
ccagTaTcaacTgcaaTTTTa
Bacteroides vulgatus
aTcc 8482
501 60
Bifidobacterium spp. cgcgTcYggTgTgaaag
ccccacaTccagcaTcca
Bifidobacterium longum 
subsp. Infantis aTcc 15697
244 60
Clostridium leptum gcacaagcagTggagT
cTTccTccgTTTTgTcaa
Clostridium leptum
aTcc 29065
239 60
Abbreviations: aT, annealing temperature; bp, base pairs; Pcr, polymerase chain reaction.
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butter fat reference standard (CRM-164, Fedelco Inc, Spain) 
were used for identification of FA. GLC-Nestlé36 (Nu Chek 
Prep, MN, USA) was assayed for calculation of response 
factors and detection and quantification limits (LOD: 
0.079 µg FA/mL; LOQ: 0.264 µg FA/mL).
Determination of short-chain fatty acids (scFa)
Supernatants from feces prepared, as aforementioned, were 
filtered through 0.20 µm cellulose acetate membranes. 
Aliquots of the filtered samples were assayed for organic 
acids (lactic, acetic, propionic, and butyric acids) by 
HPLC-RI using an Aminex HPX-87H column (Bio-Rad 
Laboratories Inc.) operated at 60°C (mobile phase 0.003 M 
of H
2
SO
4
, flow rate of 0.6 mL/minute).
statistical and mathematical analysis
One-way analysis of variance was carried out with SPSS 
version 19 (StataCorp LP, College Station, TX, USA) to 
determine the significance of the differences between the 
five conditions: RA free, Witepsol SLN empty, Carnauba 
SLN empty, Witepsol SLN-RA, and Carnauba SLN-RA 
for particle size, polydispersity index, and zeta potential 
(P,0.05).
For determination of the entrapped RA in SLN at the time 
of production, the following formula was used:
 
% Entrapped RA
RA
RA
s
extract
= −
×



100
100
 
(3)
where RA
S
 represents the concentration of RA obtained in the 
supernatant after filtration and RA
extract
 is the concentration 
of RA in the sage extract.
In the in vitro toxicity results, the effects of samples and 
concentrations were evaluated based on the percentage of 
nonviable cells obtained. In all samples, the significance 
of the differences between the mean of cell percentages 
(lowercase letters) was determined. Then, the significance of 
the differences between the mean cell percentages obtained 
using different sample concentrations was also analyzed. 
Tukey’s post hoc test was used at the 5% significance level 
and applied to all the experimental results. Biochemical 
and hematological data comparisons between groups were 
performed using nonparametric analyses using the Kruskal–
Wallis test, followed by the post hoc Dunn’s test for multiple 
comparisons, using the GraphPad Prism for Windows 
(Version 5, GraphPad Software, Inc., La Jolla, CA, USA). 
The statistical significance levels were set at P,0.05.
Results
Part a – in vitro toxicology
slN properties and encapsulated ra concentrations
Table 2 lists the SLN physical properties and association effi-
ciencies (AE, in %) of RA. Empty SLN showed lower particle 
sizes (ie, 300–500 nm) than those loaded with RA (~900 nm) 
and with herbal extract (~1,000 nm; P,0.05). Polydispersity 
indexes were within the normal values (ie, 0.100–0.300), 
and zeta potentials were negative and presented medium 
values ~-20 mV. Association efficiencies of RA and total 
phenolic compounds from extract in SLN were ~90% and 
70%, respectively. The entrapped quantities of RA from 
herbal extract in SLN were also measured and calculated to 
compare with RA pure compounds. The percentage of RA 
entrapped in SLN from herbal extracts was ~50% in Witepsol 
SLN and ~40% in Carnauba SLN. The SLN morphology pro-
duced with both type of waxes was similar when observed by 
TEM (Figure 1), and the sizes observed were slightly higher 
than those obtained by DLS technique.
genotoxicity effects
The NDI values obtained are listed in Table 3. The use 
of cyclophosphamide (positive control) induced almost a 
tenfold increase in micronucleus-forming activity, versus the 
Table 2 Physical properties and association efficiencies of WSLN and CSLN unloaded (empty) or loaded with RA (WSLN-RA and 
CSLN-RA) or with sage extract (WSLN-sage and CSLN-sage)
Nanoparticles Particle size (nm) Polydispersity index Zeta potential (mV) AE (%) RA (%)
WSLN empty 332.0±2.6a 0.345±0.090a -25.00±3.29a na na
cslN empty 511.0±4.9b 0.278±0.028a -23.90±4.90a na na
WSLN-RA 903.0±15.0c 0.123±0.055b -17.30±7.98a 92.50±0.67a na
cslN-ra 874.0±67.9c 0.304±0.031a -21.90±4.81a 97.30±0.79a na
WSLN-sage 1,007.0±21.0c 0.267±0.0140a -16.20±0.64a 79.10±0.10b 48.6
cslN-sage 927.0±20.0c 0.277±0.0210a -11.00±2.56b 79.80±0.092b 39.2
sage na na na na 60.6
Notes: Data presented as mean ± standard deviation. a–cMean value differences in the same column with the same letter are not statistically significant (P.0.05).
Abbreviations: AE, association efficiency; CSLN, Carnauba solid lipid nanoparticles; na, not applicable; RA, rosmarinic acid; WSLN, Witepsol solid lipid nanoparticles.
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3628
Madureira et al
negative control. All samples presented low values of NDI 
when used at the highest concentration (1.5 mg/mL). Free RA 
showed values of NDI of 1.42 and 1.35 for concentrations of 
0.15 and 1.5 mg/mL, respectively, and sage extract showed 
similar values (1.47 and 1.42). Carnauba empty SLN induced 
a lower NDI value (1.46) than Witepsol empty SLN (1.52).
cytotoxicity effects
At the higher concentration (1.5 mg/mL), lymphocytes treated 
with free RA showed a significant increase in nonviable 
cells when compared with the negative control (Figure 2). 
Percentages of nonviable cells were near 60% and close 
to those exhibited by the positive control – ~70% (treated 
with staurosporine). Free sage extract produced similar % of 
dead cells to negative control at both concentrations (~20%), 
slightly higher at 1.5 mg/mL (P,0.05). Empty WSLN also 
originated a % of dead cells similar to that found in the 
negative control (P.0.05), whereas a higher % of dead cells 
was found for empty CSLN (~40%). Witepsol and Carnauba 
SLN-RA at the higher concentration (1.5 mg/mL) produced 
values of cell death (~50%) similar to that encountered for 
the positive control (P.0.05). In general, low percent of dead 
cells were detected for lymphocytes treated with SLN-sage; 
Figure 1 TEM images of WSLN and CSLN loaded with RA in suspension (WSLN-RA and CSLN-RA, respectively). A scale illustrating the size is presented.
Abbreviations: TEM, transmission electron microscopy; CSLN, Carnauba solid lipid nanoparticles; WSLN, Witepsol solid lipid nanoparticles.
Table 3 Data from the cytokinesis-blocked micronucleus cytome 
assay for free compounds (RA and sage extract), and for WSLN 
and CSLN unloaded (empty) or loaded with RA (WSLN-RA and 
CSLN-RA) or with sage extract (WSLN-sage and CSLN-sage) at 
the two concentrations tested
Compound  
concentration  
(mg/mL)
Samples MN/1,000  
binucleated  
cells
NDI
0 control- 3.33±1.41 1.53
control+ 26.70±4.95* 1.39
WSLN empty 2.00±0.71 1.52
cslN empty 2.50±0.71 1.46
0.15 rosmarinic acid 2.50±0.71 1.42
sage extract 3.50±0.71 1.47
WSLN-RA 4.00±0.71 1.45
cslN-ra 3.00±1.41 1.46
WSLN-sage 3.50±2.12 1.52
cslN-sage 3.50±0.71 1.52
1.5 rosmarinic acid 4.00±0.00 1.35
sage extract 2.50±0.71 1.42
WSLN-RA 3.50±0.71 1.42
cslN-ra 3.00±1.41 1.44
WSLN-sage 2.50±0.71 1.46
cslN-sage 2.50±0.71 1.47
Notes: Data presented as mean ± standard deviation. empty slN used only one lipid 
concentration, 0.5% (m/v) for the two polyphenol and extract concentrations. *P,0.05.
Abbreviations: MN, micronucleus; NDI, nucleous division index; cslN, car nauba 
solid lipid nanoparticles; RA, rosmarinic acid; WSLN, Witepsol solid lipid nano-
particles.
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Figure 2 Nonviable lymphocytes (annexin V+/7aaD- plus annexin V+/7aaD+) (mean ± SD) after treatment with free RA, sage extract, and WSLN and CSLN at two 
concentrations.
Notes: empty slN used only one lipid concentration (0.5% [m/v]) for the two polyphenol and extract concentrations. aData not statistically significant (P.0.05) when 
compared to other data labeleda. bData not statistically significant (P.0.05) when compared to other data labeledb. *Mean value differs from positive control (c+) and is 
statistically significant (P,0.05).
Abbreviations: RA, rosmarinic acid; CSLN, Carnauba solid lipid nanoparticles; WSLN, Witepsol solid lipid nanoparticles; SD, standard deviation; C+, positive control; c-, 
negative control.
Figure 3 Necrotic (annexin V+/7aaD+) and apoptotic (annexin V+/7aaD-) lymphocytes % (mean ± SD) after treatment with free RA, sage extract, and WSLN and CSLN 
(cslN) at two concentrations.
Notes: empty slN used only one lipid concentration (0.5% [m/v]) for the two polyphenol and extract concentrations. *Mean value is different from positive control (c+) 
and is statistically significant (P,0.05).
Abbreviations: RA, rosmarinic acid; CSLN, Carnauba solid lipid nanoparticles; WSLN, Witepsol solid lipid nanoparticles; SD, standard deviation; C+, positive control; C–, 
negative control.
however, when CSLN-sage were used, the cell death fraction 
significantly increased (~50%).
Figure 3 shows the results of cell death by necrosis 
and by apoptosis. Extent of apoptosis in cells treated with 
staurosporine was ~41%; this value was significantly higher 
than that induced by RA or sage extract and by SLN, at any 
concentration tested (P,0.05). Only RA at higher concentra-
tions was able to cause a cell death % by apoptosis of ~12%, 
higher than the negative control (~5%; P,0.05). RA in the 
free from, WSLN-RA and CSLN-RA, induced significant 
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Figure 4 agarose gel electrophoresis for in vitro DNa assay.
Note: Determination of antioxidant and prooxidant effects of WSLN and CSLN.
Abbreviations: CSLN, Carnauba solid lipid nanoparticles; WSLN, Witepsol solid lipid nanoparticles; RA, rosmarinic acid; C+, positive control; c-, negative control.
cell death by necrosis – ~40% (P,0.05). Empty CSLN also 
caused significant cell death by necrosis – ~20% (P,0.05). 
In addition, CSLN-sage produced cell death of ~20% by 
necrosis.
slN effects on DNa
Figure 4 shows the agarose gel electrophoresis with the run 
samples observed in a transilluminator. The positive control 
was tested with pure RA (0.15 mg/mL) and, as expected, the 
compound demonstrated antioxidant capacity with a fluores-
cent band of DNA. All SLN loaded with RA and extract did 
not present any antioxidant capacity (absence of DNA band). 
To study the prooxidant activities, SLN solutions were added 
to a DNA solution without oxidant; as shown in Figure 4, the 
presence of bands indicates that SLN did not affect DNA, 
since an intact band of DNA was observed.
Part B – in vivo animal studies
Body and tissues weight
No significant changes of BW were observed between the five 
groups, despite a trend to an increased value in the CSLN-
RA10 group; in addition, a trend to a reduced relative weight 
of stomach and kidney, and to an increased relative weight of 
liver and spleen, was found in the same group (Table 4).
hematological and biochemical data
No changes in hematological parameters were observed 
between the groups, despite a trend toward increased platelet 
counts in the CSLN-RA10 group (Table 5). No significant 
changes on serum biochemical data were found between 
groups, excepting a trend toward reduced urea and uric 
acid in all SLN-treated groups, a significantly (P,0.05) 
reduced albumin content in the CSLN-RA10 group, as well 
as a trend toward increased TGs concentrations in all SLN-
treated groups versus the control group (Table 6).
redox status
Table 7 lists the values of redox status markers obtained in 
serum, kidney, and liver samples. While an increased serum 
MDA/TAS ratio was found in the WSLN-RA1 and CSLN-
RA1 groups (P,0.05) versus the control group, MDA levels 
in the kidney remained unchanged between groups; a reduced 
MDA content in the liver of WSLN-RA1, WSLN-RA10, and 
CSLN-RA1 groups was also observed, when compared with 
the control one (Table 7).
TeM analysis of tissues
The presence of SLN was undetectable in the tissue samples 
evaluated for both formulations and concentrations tested. 
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Table 4 BW and absolute and relative tissues weights of rats treated for 14 d with vehicle (control) or with WSLN or CSLN loaded 
with 1 or 10 mg/kg bw/d of ra
Parameters Control  
(vehicle)
WSLN-RA1  
(1 mg/kg bw)
WSLN-RA10  
(10 mg/kg bw)
CSLN-RA1  
(1 mg/kg bw)
CSLN-RA10 
(10 mg/kg bw)
BW
Initial (g) 304±4 304±4 297±2 310±4 298±12
Final (g) 340±13 353±9 340±6 338±18 362±4
Tissues weight
stomach (g) 1.82±0.14 1.80±0.07 1.72±0.00 1.81±0.09 1.75±0.08
Stomach/BW (g/kg) 5.33±0.19 5.09±0.13 5.07±0.10 5.40±0.45 4.85±0.19
liver (g) 13.24±1.33 12.98±0.32 12.71±0.27 12.61±1.17 14.52±0.5
Liver/BW (g/kg) 38.71±2.36 36.79±0.94 37.34±0.25 37.15±1.71 40.10±1.26
Kidney (g) 2.42±0.24 2.52±0.05 2.40±0.06 2.27±0.11 2.40±0.09
Kidney/BW (g/kg) 7.08±0.40 7.14±0.21 7.05±0.12 6.72±0.06 6.23±0.24
heart (g) 1.03±0.03 1.09±0.01 1.18±0.14 1.03±0.05 1.09±0.03
Heart/BW (g/kg) 3.03±0.03 3.08±0.10 3.49±0.04 3.07±0.14 3.02±0.07
lung (g) 1.33±0.08 1.42±0.03 1.44±0.05 1.37±0.03 1.40±0.06
Lung/BW (g/kg) 3.89±0.07 4.02±0.04 4.21±0.09 4.08±0.17 3.87±0.15
spleen (g) 0.66±0.03 0.71±0.02 0.70±0.04 0.75±0.11 0.85±0.03
Spleen/BW (g/kg) 1.93±0.04 2.00±0.11 2.07±0.13 2.19±0.22 2.35±0.06
EWAT (g) 4.92±0.11 4.52±0.45 3.89±0.60 4.07±0.69 4.98±0.47
EWAT/BW (g/kg) 14.47±0.39 12.77±1.18 11.48±1.89 11.97±1.59 13.76±1.31
Note: Data presented as mean ± standard error of the mean.
Abbreviations: BW, body weight; CSLN, Carnauba solid lipid nanoparticles; EWAT, epididymal white adipose tissue; RA, rosmarinic acid; WSLN, Witepsol solid lipid 
nanoparticles.
Table 5 Hematological data of rats treated for 14 d with vehicle (control) or with WSLN or CSLN loaded with 1 or 10 mg/kg 
bw/d of ra
Parameters Control  
(vehicle)
WSLN-RA1  
(1 mg/kg bw)
WSLN-RA10  
(10 mg/kg bw)
CSLN-RA1  
(1 mg/kg bw)
CSLN-RA10  
(10 mg/kg bw)
WBC count
WBC (×103/µl) 1.67±0.44 1.70±0.57 1.13±0.19 1.60±0.55 1.87±0.20
rBc counts
rBc (×106/µl) 7.10±0.15 6.93±0.07 7.13±0.18 7.00±0.25 7.13±0.03
hgB (g/dl) 13.97±0.18 13.67±0.03 13.60±0.06 13.53±0.12 13.70±0.06
hcT (%) 40.50±0.82 39.97±0.28 39.60±0.72 39.57±0.24 39.90±0.12
McV (fl) 57.30±1.26 58.10±0.87 55.47±0.58 56.60±2.37 55.90±0.00
Mch (pg) 19.77±0.39 19.83±0.24 19.03±0.35 19.37±0.89 19.17±0.03
Mchc (g/dl) 34.53±0.27 34.20±0.15 34.37±0.47 34.23±0.12 34.30±0.06
RDW (%) 12.27±0.44 12.70±0.47 13.67±0.47 13.17±0.82 13.57±0.49
Platelet counts
PlT (×103/µl) 811.00±29.61 738.00±84.69 780.70±18.21 790.70±12.71 852.50±78.81
MPV (fl) 5.80±0.17 5.73±0.03 5.80±0.31 5.87±0.13 5.97±0.15
PcT (%) 0.47±0.03 0.43±0.03 0.43±0.03 0.47±0.03 0.50±0.06
PDW 15.90±0.06 16.40±0.31 16.33±0.27 16.33±0.30 16.77±0.38
reticulocyte counts
reT (%) 2.80±0.12 3.30±0.42 3.43±0.12 3.23±0.17 3.13±0.26
IrF 0.43±0.03 0.43±0.03 0.40±0.06 0.50±0.00 0.47±0.03
MscV (fl) 62.07±0.71 62.57±1.79 59.90±0.95 61.73±1.62 61.30±0.35
hlr (%) 1.20±0.12 1.33±0.09 1.40±0.10 1.53±0.12 1.50±0.23
Note: Data presented as mean ± standard error of the mean.
Abbreviations: CSLN, Carnauba solid lipid nanoparticles; EWAT, epididymal white adipose tissue; HCT, hematocrit; HGB, hemoglobin concentration; HLR, high-
light-scatter reticulocytes; IrF, immature reticulocyte fractions; Mch, mean corpuscular hemoglobin; Mchc, mean corpuscular hemoglobin concentration; McV, mean 
corpuscular volume; MPV, mean platelet volume; MSCV, mean sphere cell volume; PCT, plateletcrit; PDW, platelet distribution width; PLT, platelet; RA, rosmarinic acid; 
RBC, red blood cell; RDW, red blood cell distribution width; RET, reticulocytes; WBC, white blood cell; WSLN, Witepsol solid lipid nanoparticles.
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Table 6 Serum biochemical data of rats treated for 14 d with vehicle (control) or with WSLN or CSLN loaded with 1 or 10 mg/kg 
bw/d of ra
Parameters Control  
(vehicle)
WSLN-RA1  
(1 mg/kg bw)
WSLN-RA10  
(10 mg/kg bw)
CSLN-RA1  
(1 mg/kg bw)
CSLN-RA10  
(10 mg/kg bw)
glucose (mg/dl) 188.00±7.51 183.70±3.76 178.70±9.68 176.30±2.33 174.00±3.51
renal function
Urea (mg/dl) 20.67±0.77 17.27±0.26 18.23±1.17 18.07±0.38 17.67±0.43
Uric acid (mg/dl) 1.07±0.07 0.87±0.12 1.03±0.28 0.83±0.19 0.73±0.15
creatinine (mg/dl) 0.30±0.00 0.23±0.033 0.27±0.03 0.23±0.03 0.27±0.03
Total proteins (g/dl) 5.50±0.00 5.37±0.07 5.43±0.07 5.40±0.12 5.17±0.12
albumin (g/dl) 3.03±0.03 2.93±0.03 2.90±0.0 2.97±0.07 2.83±0.03a
liver function
alT (U/l) 36.00±2.89 38.67±2.40 30.33±2.19 38.67±3.53 31.33±0.33
asT (U/l) 95.33±25.36 65.67±8.99 62.00±1.73 93.67±24.36 66.33±3.84
Lipid profile
Total-chol (mg/dl) 44.33±1.76 44.67±4.81 43.67±2.40 45.67±0.88 46.67±4.09
Tgs (mg/dl) 107.00±16.29 140.3±20.43 116.00±3.79 142.3±17.57 173.30±21.18
Notes: results are mean ± standard error of the mean. aP,0.05 versus the control group.
Abbreviations: alT, alanine aminotransferase; asT, aspartate aminotransferase; chol, cholesterol; cslN, carnauba solid lipid nanoparticles; Tgs, triglycerides; 
RA, rosmarinic acid; SEM, scanning electron microscopy; WSLN, Witepsol solid lipid nanoparticles.
Table 7 Serum, liver, and kidney redox status markers of rats treated for 14 d with vehicle (control) or with WSLN or CSLN loaded 
with 1 or 10 mg/kg bw/d of ra
Parameters Control  
(vehicle)
WSLN-RA1  
(1 mg/kg bw)
WSLN-RA10  
(10 mg/kg bw)
CSLN-RA1  
(1 mg/kg bw)
CSLN-RA10  
(10 mg/kg bw)
serum
MDa (µmol/ml) 1.55±0.31a 2.24±0.94a,b 1.57±0.16a 2.17±0.49a,b 1.67±0.25a
Tas (mmol/ml) 1.07±0.07a 0.90±0.18a,b 0.89±0.08b 1.09±0.16a 1.12±0.05a
MDa/Tas (×1,000) 1.51±0.42a 2.30±0.64b 1.81±0.33a 2.06±0.42b 1.52±0.26a
liver MDa (µmol/ml) 4.57±0.19a 1.93±0.77b 2.90±0.29b 2.48±0.63b 4.75±0.18a
Kidney MDa (µmol/ml) 3.31±0.34a 3.31±0.27a 3.72±0.27a 3.29±0.32a 3.15±0.23a
Notes: a,bMean values difference in the same row with the same letter are not statistically significant (P.0.05). Data presented as mean ± standard error of the mean.
Abbreviations: CSLN, Carnauba solid lipid nanoparticles; d, days; MDA, malondialdehyde; RA, rosmarinic acid; TAS, total antioxidant status; TGs, triglycerides; WSLN, 
Witepsol solid lipid nanoparticles.
Figures 5 and 6 show representative pictures of heart, liver, 
kidney, stomach, spleen, WEAT, small intestine, and cecum 
obtained by TEM for the control and WSLN-RA10 and 
CSLN-RA10. Besides the absence of deposition of SLN, 
pictures show identical ultrastructural morphological features 
for all tissues in all the groups.
gut bacterial microbiota numbers and scFa 
metabolism
Table 8 lists gut bacterial microbiota data related to rat 
groups fed with both types of SLN at the two dosages. 
Feces of rats fed with WSLN-10, CSLN-1, and CSLN-10 
showed a decrease in groups Universal, Firmicutes, 
C. leptum, and Bacteroidetes, when compared with the 
control group. In addition, feces of rats fed with WSLN 
at both dosages showed an increment on Lactobacillus 
group numbers; the other groups of bacteria were similar 
between groups.
Regarding the concentration of phenolic compounds 
in feces and small intestine, RA was undetected in the 
small intestine of control animals, while a concentration of 
0.4–0.5 mg/g tissue was found in all SLN-treated groups. 
In feces, only ferulic acid was found, in an identical con-
centration in all rat groups tested (Table 8).
The total SCFA found in feces was slightly higher in 
SLN produced with Witepsol and with Carnauba SLN-
RA1 (~3 mg/g feces; Table 8). Higher fecal butyrate and 
propionate contents were found in rats fed with SLN than 
in controls animals (P,0.05). In addition, higher fecal 
concentration of acetate was found in rats fed with WSLN, 
when compared with the control. Additionally, lower 
concentrations of lactate and succinate were found in feces 
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Figure 5 representative TeM images of heart, liver, kidney, and stomach tissue samples of rats after 14 d of oral treatments: control (vehicle-treated) rats; rats treated with 
Witepsol (WSLN-RA10) and with Carnauba (WSLN-RA10) SLN loaded with RA (10 mg/kg bw/d).
Abbreviations: C, capillary; d, days; G, Golgi apparatus; Lu, Lumen; Ly, lysosomes; MF, cardiac muscle myofibrils; Mt, mitochondria; MV, microvillus; N, nucleus; NM, nuclear 
membrane; Nu, nucleolus; rBc, red blood cells; rer, rough endoplasmic reticulum; ser, smooth endoplasmic reticulum; sg, secretory granules; TJ, tight junctions; cslN, 
Carnauba solid lipid nanoparticles; RA, rosmarinic acid; WSLN, Witepsol solid lipid nanoparticles.
of rats fed with SLN with RA encapsulated at a concentra-
tion of 10 mg/mL. The other acids were at the same range 
in all the rat groups.
Fatty acids content in slN and in rat feces
Witepsol SLN presented a higher concentration of saturated 
fatty acids (SFA; ~35 µg/mg sample) than Carnauba SLN 
(~9.6 µg/mg sample). The concentration of monounsaturated 
fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) 
was slightly higher in CSLN than in WSLN (Table 9). When 
comparing SFA, MUFA, and PUFA in feces of rats from 
both types of SLN, small differences were observed with 
unchanged values between type and dosage used (Table 10). 
In rats’ feces from all SLN groups, a trend to lower concen-
trations of medium-chain fatty acids and long-chain fatty 
acids (number of carbons higher than six) was found. In the 
WSLN groups, the concentration of C18:0 FA was slightly 
but significantly higher than in feces of rats fed with CSLN, 
owing to the composition of Witepsol. In the feces of rats 
from the SLN-10 group, a higher (P,0.05) concentration 
of hydroxyl FA (ie, C14 2-OH) was found. In addition, in 
feces of rats from all SLN groups, a higher concentration of 
the branched chain iso FA C15i, lower anteiso C15ai, and 
19-carbon cyclopropane fatty acid (C19:0 cyc) was observed 
(P,0.05). In these feces, a decrease in C18:t1 isomers (C18:1 
t6–t8) was observed. In WSLN-RA1 feces, higher concen-
trations of the isomers C18:1 t11 and C18:1t12 were found 
(P,0.05). Regarding PUFAs, a decrease in C18:2 c9c12 was 
found in feces of groups fed with WSLN. All rats fed with 
SLN suffered a decrease in C20:4 n6 (P,0.05).
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Discussion
In this study, we exploited, in vitro and in vivo, the poten-
tial toxicological effect of SLN produced with two types of 
lipidic matrices (Witepsol and Carnauba) and loaded with 
phenolic compounds: RA and sage extract.
First, the values related to the physical properties of SLN 
were in accordance to those obtained in previous works,6–8 
showing that the entrapment of RA and herbal extract in 
SLN induced an increase in particle size. The polydispersity 
index and zeta potential indicate SLN stability in solution 
and absence of agglomeration. Loading of herbal extracts 
decreased the SLN zeta potential, when compared with 
free RA. High AE percentages in SLN were found, in accor-
dance with the ones obtained in previous works.6–8 The RA 
Figure 6 Representative TEM images of spleen, EWAT, small intestine, and cecum tissue samples of rats after 14 d of oral treatments: control (vehicle-treated) rats; rats 
treated with Witepsol (WSLN-RA10) and with Carnauba (WSLN-RA10) SLN loaded with RA (10 mg/kg bw/d).
Abbreviations: AN, adipocyte nucleus; C, capillary; CM, cell membrane; d, days; EWAT, epididymal white adipose tissue; F, fibroblast; Lu, lumen; LY, lysosomes; Mt, 
mitochondria; MV, microvillus; N, nucleus; rer, rough endoplasmic reticulum; slN, solid lipid nanoparticles; TJ, tight junctions; U, unilocular adipocyte; TeM, transmission 
electron microscopy; ra, rosmarinic acid.
from herbal extract entrapped in SLN was also measured 
to compare with the RA-free sample. It is known that RA 
is found in high concentrations in sage extracts.32 The RA 
percentage present in sage was ~60%, and the real concentra-
tion of RA in sage extract was ~0.6 mg/mL. The entrapped 
concentration of RA in SLN loaded with sage was lower 
than the concentration of RA in SLN loaded with pure RA 
(~40%–50%). Hence, when producing SLN with 0.15 mg/mL 
of sage, the concentration of entrapped RA in WSLN and 
CSLN was ~0.072 and 0.059 mg/mL, respectively; these 
concentrations rose to 0.72 and 0.59 mg/mL, respectively, 
when using SLN at a final concentration of 1.5 mg/mL. In the 
SLN loaded with RA, the % of entrapped compound was 
similar to the value of AE%, since it was used pure RA and 
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Table 8 gut bacterial microbiota groups, scFa production, and concentration of phenolic acids in feces and small intestine of rats 
treated for 14 d with vehicle (control) or with WSLN or CSLN loaded with 1 or 10 mg/kg bw/d of RA
Parameters Control  
(vehicle)
WSLN-RA1  
(1 mg/kg bw)
WSLN-RA10  
(10 mg/kg bw)
CSLN-RA1  
(1 mg/kg bw)
CSLN-RA10  
(10 mg/kg bw)
Microbiota groups (number of copies)
Universal 6.46±0.20 6.24±0.35 5.66±0.12* 5.61±0.36* 5.28±0.10*
Firmicutes 6.32±0.21 6.08±0.33 5.69±0.13* 5.47±0.14* 5.33±0.13*
C. leptum 5.31±0.32 5.10±0.34 4.53±0.23 4.26±0.18* 4.23±0.16*
Lactobacillus 3.78±0.81 4.14±0.91* 4.45±0.58* 3.82±0.47 3.73±0.45
Bacteroidetes 6.29±0.25 6.07±0.41 5.52±0.04* 5.46±0.16* 5.23±0.11*
Bacteroides 5.25±0.49 5.25±0.42 5.05±0.53 5.05±0.35 4.77±0.09*
Bifidobacterium 2.36±0.40 2.78±1.12 2.20±0.45 2.36±0.20 1.98±0.70
concentration of phenolic acids (mg/g)
c(Fa) in feces 0.32±0.01 0.15±0.01* 0.20±0.09* 0.31±0.07 0.28±0.03
c(ra) in sI 0.00±0.00 0.48±0.06* 0.42±0.03* 0.42±0.08* 0.40±0.01*
scFa (mg/g feces)
TscFa 2.77±0.89 3.57±0.95 3.29±1.64* 3.34±0.06 2.30±1.11
lactate 0.17±0.09 0.22±0.09 0.11±0.03* 0.64±0.77* 0.10±0.07*
Formate 0.50±0.04 0.37±0.00 0.21±0.04 0.45±0.16* 0.37±0.14
Butyrate 0.58±0.44 0.80±0.28 0.82±0.12 1.48±0.12* 0.56±0.23
Propionate 0.44±0.12 0.89±0.37 0.90±0.39* 1.39±0.66 0.43±0.18
succinate 0.12±0.08 0.24±0.12 0.10±0.03* 0.78±0.15* 0.10±0.07
acetate 1.74±0.37 2.86±0.46 2.75±0.24 1.03±0.47* 1.31±0.53
Notes: results are mean ± sD. *P,0.05 versus control group.
Abbreviations: C. leptum, Clostridium leptum; cslN, carnauba solid lipid nanoparticles; d, days; Fa, ferulic acid; ra, rosmarinic acid; sI, small intestine; sD, standard 
deviation; TGs, triglycerides; TSCFA, total short-chain fatty acids; WSLN, Witepsol solid lipid nanoparticles.
Table 9 Fatty acid composition of WSLN and CSLN
Fatty acid WSLN CSLN
c12 13.06±0.03 nd
c14 5.71±0.07 nd
c16 7.20±0.07 2.44±0.13
c16:1 c9 0.49±0.08 0.45±0.02
c18 6.26±0.01 0.92±0.06
c18:1 c9 30.81±0.05 32.21±1.46
c18:1 11c 1.31±0.02 1.42±0.15
c22 2.20±0.25 2.96±0.09
c18:4 1.81±0.06 1.98±0.10
c22:5 n3 nd 1.07±0.03
c24 nd 3.26±0.11
µg/mg 68.84±0.30 46.73±2.15
sFa 34.42±0.23 9.59±0.40
MUFa 32.60±0.01 34.09±1.62
PUFa 1.81±0.06 3.05±0.13
Note: Fatty acid composition in µg Fa/mg sample ± sD.
Abbreviations: nd, not determined; c, cis double bond; t, trans double bond; sFa, 
total saturated fatty acids; MUFa, total monounsaturated fatty acids; PUFa, total 
polyunsaturated fatty acids; sD, standard deviation; cslN, carnauba solid lipid 
nanoparticles; WSLN, Witepsol solid lipid nanoparticles.
not extract. Therefore, in SLN loaded with 0.15 mg/mL of 
RA, the real % of entrapped RA in WSLN was 0.14 mg/mL 
and in CSLN was 0.15 mg/mL, while tenfold higher amounts 
were found (1.4 and 1.5 mg/mL, respectively) when using 
SLN loaded with 1.5 mg/mL of RA.
The nanoparticles tested in this study have the potential 
for future use as oral delivery systems of RA or polyphenol-
rich extracts. Hence, when making tests using lymphocytes, 
the goal is to evaluate the putative toxic effects if they pass 
to the blood circulation. The in vitro toxicology was assayed 
using SLN loaded with RA or with an herbal extract (sage) 
at two concentrations (0.15 and 1.5 mg/mL). The evalua-
tion of the extent of toxic effects or potential to cause injury 
upon biological systems was also performed using in vitro 
tests that are faster and ethically less demanding. In addi-
tion, they are usually more reproducible and sensitive and 
performed in a simple manner, besides allowing cellular and 
molecular reactions to be handled outside the body (ex vivo). 
The cytokinesis-blocked micronucleus cytome assay is a 
genotoxicity test that provides simultaneous information on 
a variety of chromosomal damage end points that may reflect 
chromosomal loss, breakage, and rearrangement, as well as 
gene amplification.33,34 This assay has been routinely used 
in mutagen/carcinogen screening programs to detect agents 
that cause chromosomal damage and spindle dysfunction.33,34 
In this study, micronuclei were scored in populations of 1,000 
binucleated lymphocytes, either as micronucleated binucle-
ated cells or as total number of micronuclei. When counting 
micronuclei, only once-divided, binucleated cells were 
considered, which can be obtained by blocking cytokinesis 
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with cytochalasin B, a specific inhibitor of microfilament ring 
assembly required for cytokinesis completion. Micronuclei 
are scored only in binucleated cells to avoid the effects caused 
by suboptimal or altered cell division kinetics.35 In addition, 
the NDI was used to compare the mitogenic response of 
lymphocytes and the cytostatic effects of the agents under 
study, as it provides a measure of the proliferative status of 
the viable cell fraction, thus also being a useful biomarker 
of immune function.35 The higher concentration of RA used 
(1.5 mg/mL) showed a potential for genotoxicity, in con-
trast with the lowest one (0.15 mg/mL), in which a major 
fraction of the viable lymphocytes failed to undergo cell 
division. Nevertheless, the SLN entrapped with 1.5 mg/mL 
have concentrations that are near or equal to the genotoxic 
Table 10 Fecal fatty acid composition in rats treated for 14 d with vehicle (control) or with WSLN or CSLN loaded with 1 or 10 mg/kg 
bw/d of ra
Fatty acid 
composition
Control (vehicle) WSLN-RA1  
(1 mg/kg bw)
WSLN-RA10  
(10 mg/kg bw)
CSLN-RA1  
(1 mg/kg bw)
CSLN-RA10  
(10 mg/kg bw)
Mean SD Mean SD Mean SD Mean SD Mean SD
sFa
c4 B 0.18 ,0.01 A 0.31 0.03 B 0.14 0.08 B 0.13 0.01 AB 0.34 0.20
c5 0.05 0.01 0.04 ,0.01 0.03 0.01 0.04 0.01 0.04 0.02
c6 0.03 0.01 0.01 ,0.01 0.02 0.01 0.02 0.01 0.03 ,0.01
c7 0.02 ,0.01 0.01 ,0.01 nd na Nd na 0.01 ,0.01
c9 0.01 ,0.01 0.01 ,0.01 0.02 ,0.01 0.01 ,0.01 0.02 ,0.01
c14 0.34 0.14 0.28 0.07 0.27 0.05 0.22 0.04 0.27 ,0.01
c15i B 0.19 0.04 A 0.33 0.05 AB 0.24 0.12 B 0.23 0.04 B 0.23 0.04
c15ai A 0.53 ,0.01 AB 0.41 0.10 B 0.36 0.09 AB 0.37 0.16 B 0.38 0.11
c15 A 0.67 0.11 B 0.52 0.01 A 0.57 0.01 B 0.31 0.13 A 0.57 0.10
c16i 0.14 0.04 0.10 0.02 0.11 0.01 0.11 0.07 0.07 ,0.01
c16 A 3.33 0.15 AC 2.90 0.25 BC 2.74 0.16 C 2.32 0.50 A 3.15 0.28
c17 0.18 ,0.01 0.12 0.01 0.13 ,0.01 0.09 0.04 0.13 0.01
c18 A 1.68 0.34 AB 1.53 0.01 A 1.77 0.50 C 0.87 0.23 B 1.33 0.19
c19 cyc A 0.10 ,0.01 B 0.06 ,0.01 B 0.05 0.02 B 0.05 0.03 B 0.07 0.01
c20 A 0.29 0.05 A 0.28 0.02 A 0.27 0.01 B 0.18 0.04 A 0.29 ,0.01
c22 0.28 0.04 0.27 ,0.01 0.24 0.03 0.19 0.06 0.26 0.07
c24 0.40 0.07 0.42 0.01 0.35 0.08 0.29 0.10 0.37 0.10
MUFa
c16:1 c9 0.09 0.01 0.07 ,0.01 0.05 0.01 0.07 ,0.01 0.07 0.02
c18:1 t6–t8 A 0.07 0.03 B 0.04 ,0.01 B 0.05 0.01 C 0.02 ,0.01 B 0.04 0.02
c18:1 t9 0.02 ,0.01 0.02 ,0.01 0.03 ,0.01 0.01 ,0.01 0.03 ,0.01
c18:1 t10 B 0.39 0.07 A 0.77 0.17 BC 0.38 0.14 C 0.28 ,0.01 BC 0.48 0.31
c18:1 t11 B 0.87 0.11 A 0.95 0.35 AB 0.60 0.38 B 0.38 0.23 A 0.87 0.44
c18:1 c12 0.10 0.07 0.06 ,0.01 0.07 ,0.01 0.01 ,0.01 0.07 0.06
c18:1 c9 1.68 0.26 1.60 0.03 1.39 0.14 1.53 0.02 1.72 0.52
c18:1 c11 0.28 0.02 0.25 0.02 0.22 0.06 0.19 0.04 0.27 0.05
c18:1 c12 A 0.11 ,0.01 B 0.07 ,0.01 A 0.16 0.10 C 0.01 ,0.01 B 0.06 0.02
c20:1 c9 0.08 0.02 0.08 ,0.01 0.07 0.01 0.07 0.02 0.09 0.01
c24:1 c9 0.07 0.01 0.06 ,0.01 0.05 0.01 0.04 0.01 0.06 0.01
PUFa
c12:2-Oh 0.03 ,0.01 0.04 0.01 0.04 0.01 0.03 0.01 0.04 0.01
c14:2-Oh B 0.09 0.01 B 0.08 0.01 A 0.10 0.01 C 0.06 0.02 A 0.15 0.01
c18:2 c9c12 A 2.99 0.60 B 2.62 0.02 B 2.36 0.18 A 3.03 0.08 A 2.96 1.35
c18:3 c9c12c15 A 0.23 0.04 A 0.19 ,0.01 B 0.16 0.02 A 0.24 ,0.01 AB 0.22 0.11
c20:3 n6 0.07 0.01 0.07 0.03 0.06 0.04 0.03 0.02 0.05 0.01
c20:4 n6 A 0.13 ,0.01 B 0.10 0.01 C 0.05 0.02 B 0.09 0.02 C 0.07 0.02
c20:5 n3 A 0.13 0.01 AC 0.09 0.03 0.05 0.03 BC 0.07 0.01 BC 0.07 0.05
c22:6 n3 0.09 0.01 0.09 0.01 0.06 0.02 0.08 0.01 0.08 0.02
µg/mg A 15.95 0.66 AB 14.84 1.07 B 13.24 1.05 B 11.65 1.85 A 14.95 2.24
Notes: Bold values indicate statistical significance (P,0.05). Fecal fatty acid composition in µg Fa/mg sample ± sD. letters A, B and C represent statistically significant 
differences (P,0.05) between groups, as follows: same letter (A or B or C) in two or more groups means that they are statistically identical. Different letters in two or 
more groups means that they are statistically different.
Abbreviations: nd, not determined; na, not applicable; ai, anteiso; i, iso; c, cis double bond; Oh, hydroxy fatty acid; t, trans double bond; cyc, cyclopropane; cslN, carnauba 
solid lipid nanoparticles; RA, rosmarinic acid; WSLN, Witepsol solid lipid nanoparticles; SD, standard deviation; SFA, total saturated fatty acids; MUFA, total monounsaturated 
fatty acids; PUFa, total polyunsaturated fatty acids.
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concentration (owing to the AE%) but did not demonstrate 
genotoxic effects. The empty SLN produced with Carnauba 
(CSLN) induced a decrease in NDI values, which were 
higher than those produced with WSLN, showing superior 
genotoxicity potential. In fact, the values found for the empty 
WSLN were close to those obtained for the negative control 
(P.0.05). However, no genotoxic effects were shown by the 
Carnauba SLN with RA and with sage in the higher concen-
tration (1.5 mg/mL). In addition, the SLN loaded with sage 
have RA concentrations (0.55 and 0.72 g/mL) that are not 
in the genotoxic range.
To complement in vitro toxicity data, flow cytometry 
was also used to provide rapid, quantitative, and reliable 
evaluation of cell viability; this assay has become the method 
of choice to evaluate apoptosis and necrosis in a variety of 
cell systems. Cell death can occur in two ways: by physi-
ological or by pathological means. Physiological cell death 
is distinguished by apoptotic morphology, including chro-
matin condensation, membrane blebbing, internucleosomal 
degradation of DNA, and apoptotic body formation. Patho-
logical cell death or necrosis is associated with cellular 
swelling and collapse, without severe damage to nuclei or 
DNA breakdown. This process initiates an inflammatory 
response in the surrounding tissue, thus preventing nearby 
phagocytes from locating and eliminating the dead cells by 
phagocytosis.36 In apoptosis, several cellular and molecular 
biological features are exhibited, including cell shrinkage 
and DNA fragmentation.37 Thus, we choose this method 
to provide a broader understanding of the cytotoxic effects 
of SLN upon lymphocytes. The values obtained using this 
approach indicate that RA and SLN loaded with RA at the 
higher concentrations induced a cell death percentage (~60% 
and 50%, respectively) near that found for the positive con-
trol (~75%). Regarding SLN loaded with RA, a significant 
percentage of cell death was found; however, a great part of 
cells underwent cell division, as indicated by the NDI values 
obtained. It should be hypothesized that the first contact of 
SLN with cells initiates the process of cell death but does not 
eliminate the cell’s ability to divide since these SLN were 
unable to show genotoxic effects. In addition, Carnauba 
induced an increase in cell death, in SLN loaded with RA 
and herbal extract, thus confirming the slight genotoxic 
effects previously mentioned. To sum up, our results showed 
that Carnauba SLN were able to promote cell death, which 
failed to divide.
Further analysis with flow cytometry was performed to 
evaluate the percentage of apoptotic and necrotic cells in 
the lymphocyte populations treated with SLN or with free 
compounds. The double-staining Annexin V/7-AAD assay 
discriminates cells that undergo early or late apoptosis from 
those that become necrotic.38 Overall, in this study, the major 
event encountered was necrosis, suggesting that cell death 
occurs by damage and metabolic collapse of cell membrane 
constituents of lymphocyte instead by DNA fragmentation, 
as occurs when apoptosis prevail. To further prove the 
inexistence of DNA fragmentation, an assay of agarose gel 
electrophoresis was performed, which evaluates prooxidant 
or antioxidant properties of SLN when exposed to copper 
sulfate (II)-evoked free radicals, and consequent DNA 
fragmentation or protection, respectively. It is well known 
that RA has potent antioxidant properties that afford health 
benefits;39 however, nanomedicine research must assess the 
possibility of nanoparticles-encapsulated compounds to 
cause cellular damage, with modifications of macromolecules 
(eg, DNA and proteins), thus acting as prooxidants.39 In our 
study, the absence of antioxidant activity by all SLN tested 
(absence of DNA band) was found, which could be most 
probably explained by the total incorporation of RA. Thus, 
it is concluded that SLN produced by both lipid matrices do 
not damage DNA chains but also do not protect it, showing 
an overall neutral effect.
The second part of this study was devoted to evaluate the 
safety profile of SLN loaded with RA in rats orally treated 
for 14 days. It is known that RA absorption is slower when 
compared to other phenolic acids, such as caffeic acid.40,41 
In agreement, we chose to test two dosages of RA (1 and 
10 mg/mL) encapsulated in Witepsol and Carnauba SLN. 
Regarding the quantification of RA or phenolic acids that can 
be derived from this polyphenol, our results showed detect-
able concentrations only in the small intestine of SLN-treated 
rats. Overall, our study demonstrated unchanged variation of 
BW between groups, as well as in terms of tissues (stomach, 
liver, kidneys, heart, lungs, spleen, and epididymal white 
adipose) weights. Additionally, rats treated with Witepsol 
or Carnauba SLN loaded with RA (1 or 10 mg/kg bw/d) 
presented a hematological profile (regarding WBC, RBC, 
platelet, and reticulocyte measures) identical to that found for 
the control animals. The same absence of effects was found 
regarding glycemia and serum markers of renal and liver 
function and lipid profile, except a reduction in serum albu-
min levels in the CSLN-RA10 group and a trend to increased 
serum concentration of TGs in all SLN-treated rats versus 
the control group, which will be further discussed in rela-
tion to gut and feces results. In general, it can be concluded 
that all oral SLN-based treatments evaluated are safe, pre-
senting unchanging hematological and biochemical data, 
thus demonstrating lack of myelotoxicity, nephrotoxicity, 
and hepatotoxicity. In addition, no deposition of SLN in 
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all the tissues evaluated (by TEM) was found, and RA and 
metabolites were absent from urine, suggesting that SLN are 
decomposed and RA distributed by tissues, where they could 
exert their cytoprotective actions. In fact, at least in the liver, 
an antioxidant effect is predicted, as viewed by the reduced 
lipid peroxidation in the rat groups treated with WSLN-RA 
(1 and 10 mg/kg bw/d) and with CSLN-RA1.
The nanoparticles tested in this study have the potential 
for future use as oral delivery systems of RA or polyphenol-
rich extracts in dairy matrices, thus avoiding the interactions 
that occur with matrix components, which are responsible 
for the reduced bioavailability.42,43 The release of RA from 
SLN in the intestine can protect the polyphenols from 
gastric and intestinal juices effects, especially from intes-
tinal microflora activity, thus improving bioavailability 
and retaining their beneficial biological properties. While 
unchanged values of ferulic acid (a metabolite of RA) were 
found in feces between SLN-treated rats and the control 
ones, intact RA was found in the small intestine of all rat 
groups treated with Witepsol SLN or with Carnauba SLN, 
contrasting with undetectable values obtained in the control 
animals. This finding suggests that the RA entrapped in 
SLN is released at the gut, being adsorbed and/or used by 
gut bacteria, where it can exert antimicrobial or bacterio-
static activities.44 Regarding the impact of treatments on gut 
bacterial microbiota groups, the formulation of WSLN-RA1 
was the more innocuous one, showing unchanged number 
of all bacteria analyzed (Universal, Firmicutes, C. leptum, 
Bacteroidetes, Bacteroides, and Bifidobacterium), excepting 
a reduced number of Lactobacillus; however, the animals 
treated with 10 mg/kg bw/d of RA encapsulated in WSLN 
showed a reduction in the number of Universal, Firmicutes, 
and Bacteroidetes and an increased number of Lactobacillus. 
Concerning the rats treated with Carnauba-based SLN, a 
reduced number of almost all bacteria analyzed was found, 
which was even more evident in the group treated with the 
highest RA dose.
In agreement with the impact on gut bacterial microbiota, 
the WSLN-RA1 was the most innocuous one, with unchanged 
feces concentrations of TSCFA, lactate, formate, butyrate, 
propionate, succinate, and acetate, despite a trend toward 
increased butyrate; this FA is particularly important for colon 
health because it is the primary energy source for colonic 
cells and has anticarcinogenic as well as anti-inflammatory 
properties.45,46 The most relevant differences were found for 
WSLN-RA10, in agreement with the expected impact of RA 
on SCFA fecal excretion previously reported by other authors 
using a rosemary extract in lean versus obese rats.45,46 In fact, 
SCFA, also referred to as volatile FA, are those containing 
an aliphatic tail of less than six carbon (C) atoms; they are 
produced when dietary fiber is fermented in the colon, which 
in this study is provided in the regular rat chow. Higher con-
centrations were found for butyrate and propionate, although 
within the normal range expected in rat feces.47 Concerning 
longer fatty acids, the composition of SLN was in agree-
ment with that described by the wax manufacturers. In fact, 
Witepsol SLN wax contain more SFA than Carnauba (34.42 
and 9.59 µg FA/mg sample, respectively), owing to the high 
concentration of lauric (C12) and myristc (C14) acids in the 
Witepsol wax. MUFAs (namely, oleic acid – C18:1 c9) were 
present in both waxes at identical amount (~30 µg FA/mg 
sample); in contrast, PUFAs, namely, eicosapentaenoic acid 
(EPA: C22:5 n3), were at higher concentrations in Carnauba 
wax than in the Witepsol one. Since PUFAs are considered to 
have more potential for toxicity,48 when compared with SFA, 
waxes should be carefully inspected regarding toxicologi-
cal effects, namely, Carnauba wax, which showed a higher 
content of these FAs. Our results demonstrate a decreased 
PUFA content in feces in all SLN-treated groups. This was 
accompanied, mainly in the groups with the higher dose of 
RA encapsulated in the SLN, by an increased concentration 
of hydroxyl FA tetradecadienoylcarnitine (ie, C14 2-OH), 
which are initial intermediates of PUFA-saturation metabo-
lism. Hydroxy fatty acids are probably of great importance 
because of their presence in lipid A, which is a highly con-
served region of bacterial lipopolysaccharides. In addition, 
some variations on the gut bacteria membrane lipids were 
found, such as anteiso C15 and 19-carbon cyclopropane 
fatty acids (C19:0 cyc), suggesting that it could result from 
bacterial death. The hypothesis of SLN being absorbed by 
intestinal epithelium is not being taken into account since 
TEM micrographs showed that the tissue was clean (regard-
ing nanoparticles deposition). Furthermore, the presence of 
measurable concentrations of RA in the small intestine in 
the SLN-treated rats, contrasting with the absence in control 
animals, clearly indicates that SLN are metabolized at the 
intestine, where the encapsulated RA and the lipid content 
are released. The altered composition of fatty acids in feces 
and the increased amount of TGs in serum of SLN-treated 
rats are in agreement with this hypothesis.
Conclusion
It is concluded that the sage extract, in free or in loaded form, 
has no genotoxic and cytotoxic effects in lymphocytes, with 
no DNA fragmentation. In addition, free or loaded RA was 
safe at a low dose but is able to cause genotoxicity, namely, 
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necrosis, when used at a higher dose. Regarding the vivo (rat) 
oral treatment, no toxicological effects were found, namely, 
concerning hematological data and renal and liver function 
measures; on the contrary, an antioxidant effect in the liver 
tissue was observed, and minor changes were encountered on 
gut bacterial microbiota composition and metabolism. All the 
tissues analyzed were clean concerning SLN deposition, with 
RA only measurable in the small intestine. Since no polyphe-
nols or derivatives were found in feces, it is concluded that all 
RA is metabolized and adsorbed by the small intestine, where 
SLN are metabolized. The unchanged fatty acid composition 
in feces and the increased serum TG content in SLN-treated 
rats suggest that the RA released by degraded SLN, as well 
as their lipidic component are absorbed to be used.
Collectively, our data suggest that both types of nanopar-
ticles are safe when loaded with a moderate concentration of 
RA, without in vitro genotoxicity and cytotoxicity and with 
an in vivo safe profile in rats orally treated, thus opening new 
avenues for use in commercial nutraceutical applications.
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